Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PCTP | Q9UKL6 | 1/20 | 0.32 |
| ▸ | STARD10 | Q9Y365 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31119438 | 0.78 | KMT2A (0.40) | LMNAHTTKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL31119425 | 0.78 | L3MBTL1 (0.42) | LMNAHTTKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL11767521 | 0.78 | L3MBTL1 (0.42) | LMNAHTTKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL12199226 | 0.73 | LMNA (0.33) | LMNAHTTKMT2AL3MBTL1 | |
| SCHEMBL996540 | 0.73 | KMT2A (0.44) | LMNAHTTKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL7412921 | 0.71 | KMT2A (0.40) | LMNAHTTKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL1979476 | 0.69 | KMT2A (0.46) | LMNAHTTKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL11256258 | 0.69 | KMT2A (0.42) | LMNAHTTKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL29457422 | 0.69 | LMNA (0.36) | LMNAHTTKMT2AL3MBTL1KDM4E | |
| SCHEMBL3674235 | 0.69 | LMNA (0.43) | LMNAHTTKMT2AL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888529-A2 | 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | Wyeth (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2006-11-23 | — | — | US | disclosed |
| WO-2006124692-A2 | 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | TNNI3K, CSNK1A1L, CDKL1 | LMNA 2364/4885HTT 4249/4885KMT2A 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.